✦ LIBER ✦

New drug regimen for oesophagogastric cancer?

✍ Scribed by Claire Tilstone

Book ID: 117784608
Publisher: The Lancet
Year: 2008
Tongue: English
Weight: 68 KB
Volume: 9
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(08)70015-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacotherapy for Oesophagogastric Can

Pharmacotherapy for Oesophagogastric Cancer

✍ Christopher Jackson, Naureen Starling, Yu Jo Chua, Professor David Cunningham 📂 Article 📅 2007 🏛 Springer International Publishing AG 🌐 English ⚖ 156 KB

Neoadjuvant therapy for oesophagogastric

Neoadjuvant therapy for oesophagogastric cancer

✍ F. Lordick; H. J. Stein; C. Peschel; J. R. Siewert 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 1 views

Acid, helicobacter and immunity: a new p

Acid, helicobacter and immunity: a new paradigm for oesophagogastric cancer

✍ Michael J.G. Farthing; Rebecca Fitzgerald; Zun Wu Zhang 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 115 KB

New treatment regimen for thyroid cancer

✍ Cathel Kerr 📂 Article 📅 2003 🏛 The Lancet 🌐 English ⚖ 76 KB

Capecitabine vs oxaliplatin for advanced

Capecitabine vs oxaliplatin for advanced oesophagogastric cancer

📂 Article 📅 2005 🏛 Adis International Limited (now part of Wolters Kl ⚖ 120 KB

544 ECF is a highly active regimen with

544 ECF is a highly active regimen with low toxicity suitable for neoadjuvant treatment of oesophagogastric cancer

✍ P. Ross; D. Cunningham; A. Norman; M. Hill 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 162 KB